DLL3 has been shown to have anticarcinogenic effects in glioma, hepatocellular carcinoma and malignant glioma, but procarcinogenic effects in SCLC, pituitary tumors, and acute myeloid leukemia. The gene discussed is DLL3; the disease is glioma.